Thursday, November 21, 2024
11/21/2024
Malaria continues to be among the world’s most virulent infectious diseases accounting for the death of ~0.4 million people a year. Unlike many viral infections, children usually have repeated clinical episodes, but by adulthood, the majority of individuals living in endemic areas are protected against disease, not parasite carriage. The reasons for this gradual response to the parasite are not well established. Eventually antibodies are produced in adults that reduce parasitemia and fever when passively transferred to children with malaria, indicating a role for antibody-mediated immunity. However, it has been difficult to study this slow development of immunity to natural infection in the field, since there is no way to control for parasite strain or exposure timing. Animal studies, while allowing controlled inoculations of specific parasite strains, are complicated to apply to human infections due to differences across host and parasite species. To address these limitations, we carried out a clinical trial to systematically evaluate the immune response of malaria-naïve volunteers to an initial exposure to uninfected mosquitoes, followed 2 months later with Plasmodium falciparum (Pf)-infected mosquito bites and then 2-3 subsequent challenges each with the mosquitoes infected with the same strain of Pf. The use of the controlled human malaria infection (CHMI) model allowed control of the timing of parasite exposure and therefore the early response to sequential infections could be directly monitored. As observed with children in malaria endemic countries, the initially naïve volunteers continued to be susceptible through the multiple infectious challenges, but the time to a positive blood smear, termed patency, increased significantly overtime. Symptoms decreased significantly by the 3rd and 4th challenges indicating the beginning of clinical immunity and preliminary data indicates plasma from the two subjects with the longest patency delay reduced liver cell invasion consistent with the development of pre-erythrocytic immunity. This unique, well- controlled infection model allows us to carefully follow the production of antibody-secreting plasma cells and parasite-specific memory B cells from before parasite exposure through 3 to 4 challenges with mosquitoes infected with the same strain of P. falciparum. Our preliminary analysis of the antibody repertoire of circulating plasma cells demonstrates marked clonal expansion followed by population collapse and the appearance of distinct clones. We hypothesize that B cells stimulated by the parasite proliferate and differentiate preferentially into plasma cells, not memory cells. Such a model could explain the lack of a sustained memory response to infection and subsequent delay in the acquisition of immunity. The specific aims are 1) Characterize parasite- specific memory B cell production through repeat challenges. 2) Evaluate parasite-specific memory B cells isolated after each CHMI to parasite stimulation in vitro. 3) Assess the Pf liver and blood stage growth inhibition through repeated CHMI. Together the results will advance our understanding of the memory response to Plasmodium, which is critical for the development of protective immunity.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
